Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

被引：2

作者：

Brieva, Luis ^{[1
]}

Estruch, Bonaventura Casanova ^{[2
]}

Merino, Juan Antonio Garcia ^{[3
]}

Meca-Lallana, Virginia ^{[4
,5
]}

Rio, Jordi

Rodriguez-Antigueedad, Alfredo ^{[6
]}

Aguera, Eduardo ^{[7
]}

Ara, Jose Ramon ^{[8
]}

Luque, Adrian Ares ^{[9
]}

Garcia, Carmen Arnal ^{[10
]}

Blanco, Yolanda ^{[11
]}

Castillo-Trivino, Tamara ^{[12
]}

Costa-Frossard, Lucienne ^{[13
]}

Platas, Montserrat Gonzalez ^{[14
]}

Pascual, Lamberto Landete ^{[15
]}

Llaneza-Gonzalez, Miguel ^{[16
]}

Gines, Maria Luisa Martinez ^{[17
]}

Matias-Guiu, Jorge ^{[18
]}

Meca-Lallana, Jose E. ^{[19
]}

Bilbao, Mar Mendibe ^{[6
]}

Sempere, Angel Perez ^{[20
]}

Romero-Pinel, Lucia ^{[21
]}

Saiz, Albert ^{[22
]}

Moral, Ester ^{[23
,24
]}

机构：

[1] IRBLLEIDA, Hosp Arnau Vilanova, Lleida, Spain

[2] Hosp Universitari i Politecn Fe, Dept Neurol, Unit Neuroimmunol, Valencia, Spain

[3] Univ Autonoma Madrid, Fdn Invest Puerta Hierro, Madrid, Spain

[4] Hosp Univ Princesa, Dept Neurol, Multiple Sclerosis Unit, Madrid, Spain

[5] Hosp Univ Vall dHebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya, Serv Neurol Neuroimmunol, Barcelona, Spain

[6] Hosp Univ Cruces, Neuroimmunol & Multiple Sclerosis Unit, Baracaldo, Spain

[7] IMIBIC, Hosp Univ Reina Sofia, Neurol, Cordoba, Spain

[8] IIS Aragon, Hosp Univ Miguel Servet, Zaragoza, Spain

[9] Complejo Asistencial Univ Leon, Neurol, Leon, Spain

[10] Hosp Virgen Nieves, Granada, Spain

[11] Hosp Clin Barcelona, Un Neuroimmunol & Esclerosis multiple, Barcelona, Spain

[12] Biodonostia Hlth Res Inst, Neurol Dept, Basque Hlth Serv, Neurosci Area,Multiple Sclerosis Grp, San Sebastian, Spain

[13] Hosp Univ Ramon & Cajal, Fdn Invest Biomed IRyCIS, Serv Neurol, CSUR Esclerosis Multiple, Madrid, Spain

[14] Hosp Univ Canarias, Serv Neurol, Tenerife, Spain

[15] Hosp Univ Dr Peset, Serv Neurol, Valencia, Spain

[16] Complejo Hospitalario Univ Ferrol, Serv Neurol, La Coruna, Spain

[17] Hosp Gen Univ Gregorio Maranon, Serv Neurol, Madrid, Spain

[18] Univ Complutense Madrid, Hosp Clin San Carlos, Hlth Res Inst San Carlos IdISCC, Dept Neurol, Madrid, Spain

[19] IMIB Arrixaca, Hosp Clin Univ Virgen Arrixaca, Neurol Dept, CSUR Multiple Sclerosis & Clin Neuroimmunol Unit, Murcia, Spain

[20] Hosp Gen Univ Alicante, Neurol Serv, Alicante 03010, Spain

[21] Hosp Universitari Bellvitge IDIBELL, Dept Neurol, Multiple Sclerosis Unit, Lhospitalet De LLobregat, Barcelona, Spain

[22] Univ Barcelona, Hosp Clin, Inst Invest Biome August Pi Sunyer IDIBAPS d, Ctr Neuroimmunol, Barcelona, Spain

[23] Hosp Moises Broggi, Serv Neurol, Sant Joan Despi, Barcelona, Spain

[24] Hosp Gen Hospitalet, Serv Neurol, Lhospitalet De Llobregat, Barcelona, Spain

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 63卷

关键词：

Relapsing multiple sclerosis; Disease modifying therapy; Benefit-risk; Therapy switching; Relapse; Washout period; INTERFERON-BETA; NATALIZUMAB; FINGOLIMOD; GUIDELINES; PREGNANCY; OUTCOMES; IMPACT; MRI;

D O I：

10.1016/j.msard.2022.103805

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: The increase in available disease modifying therapies (DMTs) for multiple sclerosis has led to greater emphasis on improving treatment sequencing paradigms. This article summarises the opinions from a panel of 25 experts on treatment switching approaches in relapsing multiple sclerosis (RMS).Methods: A modified Delphi consensus process was carried out to develop clinically relevant statements for aiding treatment decisions in patients with RMS between the 16th January and the 9th October 2019. A sub-group of two experts (core group) carried out an extensive review of the literature and formulated 106 statements for the expert panel to evaluate.Results: From a total number of 106 statements that were submitted to the expert panel for critical evaluation, consensus (at least 80% of the panelists agreed) was reached on 99 of them. These statements cover treatment objectives, reasons for DMT switching, suboptimal response criteria, strategies for treatment change and washout periods.Conclusion: The agreed statements provide up-to-date guidance on DMT sequencing for optimal patient management.

引用

页数：8

共 50 条

[21] Factors Impacting Disease Modifying Therapy Transition in Relapsing Remitting Multiple Sclerosis
Chu, N.
McCombe, J.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 51 - 51
[22] Disease-modifying therapy in adult relapsing-remitting multiple sclerosis
Rosenzweig, Tamara M.
Hartman, Sarah
MacKenzie, Elizabeth
FORMULARY, 2010, 45 (08) : 252 - 262
[23] The American Academy of Neurology (AAN) guideline on the use of disease modifying therapy in multiple sclerosis
Rae-Grant, A. D.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 70 - 71
[24] Discontinuation of Disease-Modifying Therapy for Patient with Relapsing-Remitting Multiple Sclerosis
Yano, Hajime
Gonzalez, Cindy T.
Healy, Brian C.
Glanz, Bonnie I.
Weiner, Howard L.
Chitnis, Tanuja
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 47 - 47
[25] Disease-modifying therapy in relapsing-remitting multiple sclerosis: efficacy is paramount
Cristiano, E
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 3 - 7
[26] Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis
Parks, Natalie E.
Andreou, Pantelis
Marrie, Ruth Ann
Fisk, John
Bhan, Virender
Kirkland, Susan A.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
[27] The Effects of Disease Modifying Therapy on Retinal Structures in Relapsing Remitting Multiple Sclerosis Patients
Gilroy, Melody
Lichtman-Mikol, Samuel
Darling, Rachel
Santiago-Martinez, Carla
Bernitsas, Evanthia
NEUROLOGY, 2019, 92 (15)
[28] The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement
Moiola, Lucia
Barcella, Valeria
Benatti, Simone
Capobianco, Marco
Capra, Ruggero
Cinque, Paola
Comi, Giancarlo
Fasolo, Maria Michela
Franzetti, Fabio
Galli, Massimo
Gerevini, Simonetta
Meroni, Luca
Origoni, Massimo
Prosperini, Luca
Puoti, Massimo
Scarpazza, Cristina
Tortorella, Carla
Zaffaroni, Mauro
Riva, Agostino
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 331 - 346
[29] Switching Between Disease Modifying Treatment for Relapsing Remitting Multiple Sclerosis, a Retrospective Review of Practice at a Regional Multiple Sclerosis Centre in England
Clark, Deborah
Jones, Shelley
Brex, Peter
Bates, Ian
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 382 - 382
[30] Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
Roos, I.
Malpas, C.
Leray, E.
Casey, R.
Horakova, D.
Havrdova, E. Kubala
Debouverie, M.
Patti, F.
De Seze, J.
Izquierdo, G.
Eichau, S.
Edan, G.
Prat, A.
Girard, M.
Ozakbas, S.
Grammond, P.
Zephir, H.
Ciron, J.
Maillart, E.
Moreau, T.
Amato, M. P.
Labauge, P.
Alroughani, R.
Buzzard, K.
Skibina, O.
Terzi, M.
Laplaud, D.
Berger, E.
Grand'Maison, F.
Lebrun-Frenay, C.
Cartechini, E.
Boz, C.
Lechner-Scott, J.
Clavelou, P.
Stankoff, B.
Prevost, J.
Kappos, L.
Pelletier, J.
Shaygannejad, V.
Yamout, B.
Gerlach, O.
Spitaleri, D.
van Pesch, V.
Gout, O.
Turkoglu, R.
Heinzlef, O.
Thouvenot, E.
Vukusic, S.
Butzkueven, H.
Kalincik, T.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 673 - 676

← 1 2 3 4 5 →